Buyout
Aug 03, 2017
Allergan sell; AZ, Merck team up; Roche’s MS drug; Chinese API maker receives a warning letter
Allergan can finally sell its losing stake in Teva. Will it? Allergan, which acquired a 9.9% stake in the Israeli drugmaker last year as part of the pair’s $40 billion-plus generics deal, currently stands as Teva’s largest shareholder. Those shares, worth $5.3 billion when Allergan acquired them, have been locked do...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
